you. Thank
visual patients product XLRP, Sue X/X evaluating our fields AAV States The young with United the legal we our men. in Biogen in multiple study take at and time novel treatment candidate of the now an over AGTC’s place night leads As to vector, disease trial, for gene. assess and in boys, RPGR collaboration safety are adult that across primarily efficacy blindness of mentioned, will constricted recombinant clinical centers optimized causing a expressing blindness initially and affects the and enrolling Phase
We additional for five active across dose United two have dosed patients screened three study second at have States. in additional or now sites, the and group the scheduled adding including patients sites screenings
the dose escalation complete in trial to We of the quarter expect the of phase first XXXX. XLRP
Turning and to poor disease, inherited retinal light. in achromatopsia, which to discrimination our color sensitivity from programs clinical to suffer loss an of develop vision, for patients treatments
pool group. genotyping and we most In Phase presently AGTC’s for begin three begun X we enrollment. common their has CNGBX in caused the third trial, in achromatopsia enrollment in groups. achromatopsia patients to Israel achromatopsia clinical achromatopsia mutations of And in are in two have low candidates CNGBX product the CNGAX order site enrolled patients dose X In by X patients the completed enrolling We across international of dose CNGAX. genes, and screening the X/X patient have trials our trial,
escalation achromatopsia to phase of dose in thereafter. first of expect the complete BX to quarter trial follow the AX XXXX with the We achromatopsia
same differentiation for capsids development achromatopsia candidates gene of fundus non-human a in obtain by our were in capsids expression for performed photoreceptor reported a XLRP revealed achromatopsia specifically and attractive believe eyes three comparative subretinal There subretinally using achromatopsia therapy product in clinical XX Phase continue programs. we gene the having and a we our comparable and evaluate the This PCR including In and for levels control that both we XLRP higher product of to our AAV the addition analysis. vectors our choice fluorescence capsids injection. two same of advantage and are under X/X that therapeutic products, understand received these weeks. to data, transduction XLRP while our and delivered we ongoing results on volume immunohistochemistry. a settings. specific clinical have compared an Non-human To for the To analysis of recently preclinical primates therapy other programs, of our followed versus have currently in via the we’ve expression and that this safety gene competitive photoreceptor and candidates others, Based results efficiency the relative of of via of the to experiment, injections both vector concentration head-to-head promoter. analysis for primate represent
resulting adult Turning progress Phase trial or XLRS of young X/X our we’ve boys. layers patients. is disease that abnormal a in with x-linked poor the candidate in men. characterized in collaboration of functioning XLRS now to in the recently retinoschisis blindness by for This can is XX to Biogen, the completed in splitting our clinical of legal product targeted visual retina enrollment
Additionally, of stage are approximately patients hemorrhage life. at at their risk of retinal or detachment of XLRS any XX%
the interim months the safety analysis analyzing candidate number to of trial that retinal safety and and safe function, a available Although, six-months to measuring provide The measure activity support trial data data end this biologic endpoints also and with to life of visual clinical will data this Company in is the quality the by top-line across well-tolerated, full activity expects trial primary endpoint XLRS follow and primary XXXX of product our active of is later. assessments. both six wide generally continue by XX-month structure changes biological of
and the data for in generally Biogen collaboration product the patients well-tolerated to pediatric pediatric with in population. safe decided high also patients include as to in trial the supported middle XLRS have this the that patient dose expand candidate the dose group We at was five
visual who’ll approaches. over functioning programs turn In addition quarter optogenetic brain Sight retinal would than IND device the novel for ongoing Sullivan, expects from the protein, to to studies, on file Bill product electrical candidate genes with device a light-sensitive device, we use candidate proteins normally using with early to financial to the Sight XXXX. of disease. patients and control the prosthesis. review signals, the of the continue without Bionic images, year This to other potentially this kinds their our function. function proof-of-concept in visual the for photoreceptors as retinal for may will to product photoreceptors. allowing now same retinal advanced regain activity them half The introduce developing normally fourth call into light four development Bionic of and Bionic converts product patients fiscal partner receives of cells into a have patterns that a the its known with light-sensitive is optogenetic patients then on The to processes Sight pulses allow them better first I briefly receives of results. XXXX functional vision-enhancing clinical based
